The MoU will help in advancement of neuro-oncology research for treatment of malignant brain tumour cancer
A Memorandum of Understanding (MoUs) has been signed between SBF Healthcare and University of California, Los Angeles (UCLA) and University of Pennsylvania for advancement in neuro-oncology research for treatment of malignant brain tumour cancer. According to the new bill announced by the US President, Donald Trump on ‘Right to Try Law’, SPMF Therapy can be used for treatment by any US citizen without any FDA approval.
Speaking on the occasion, Wg Cdr (Dr) VG Vasishta, said, “There is a major need for non-surgical intervention without any side effects in the treatment of cancer. SPMF Therapy provides a non-invasive and safe treatment without any side effects. It halts the progression of the disease and improves quality of life and extends the survival period. It also helps develop a patient’s emotional and psychological well being. This therapy has proven to be a miracle for many patients with malignant tumours and is now set to help make progress in fields of neuro-oncology research through our association with two leading universities in the US. Until today, India has been relying on Western countries for advanced medical treatment and techniques. I am extremely delighted that, with SPMF Therapy, we are setting the ground for an Indian medical technology to be used by people across the globe for treating a complex disorder such as brain tumours. For the first time, an advanced medical technology developed by an Indian will be approved to be used for the treatment of brain tumours in the US.”
The event also witnessed showcase of success stories of brain tumour patients who have been treated using SPMF therapy.
To commemorate World Brain Tumour Day observed, SBF Healthcare also announced the launch of its Brain Tumour Programme. The healthcare centre will run a week-long consultation programme for cancer patients starting from June 12, 2019.